Benitec Biopharma Inc. (BNTC) Stock Price & Analysis
Benitec Biopharma Inc. (BNTC) closed at USD 8.46 on Thursday, October 15, 2026, up 2.05% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 8.29; the Oct 15, 2026 session ranged USD 8.34–8.76 on volume of 153,730 shares. Market capitalization is $295.11M, with a 52-week range of USD 8.25–16.76 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BNTC.md
Key facts (BNTC)
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 24.33 (range 17–32).
- Total return with dividends: 1Y -46.1% vs S&P 500 +18.1%; 5Y -86.1% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.28, revenue estimate $0K.
Analysts (BNTC)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 24.33 (low 17, high 32).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-15 | Wedbush | Target raised | Outperform | $16 → $17 |
| 2026-07-28 | Wedbush | Initiated | Outperform | $16 |
Total return (dividends reinvested) (BNTC)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -46.1% | -86.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -46.2% | -32.6% |
| Volatility (annualized) | 61.5% | 82.8% |
| Max drawdown | -49.8% (Oct 2025→Oct 2026) | -96.5% (Oct 2021→Jul 2023) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 8.46 |
|---|---|
| Change | ▲ 2.05% (up) |
| Previous Close | USD 8.29 |
| Open | USD 8.37 |
| Day Range | USD 8.34 – 8.76 |
| 52-Week Range | USD 8.25 – 16.76 |
| Volume | 153,730 shares |
| Market Cap | $295.11M |
| Exchange | NCM |
Technical Analysis (BNTC)
Nexqual's technical model rates BNTC "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.85 (oversold) |
| vs SMA50 | Below (USD 11.36) |
| MACD | -0.82 (negative) |
Analyst Ratings (BNTC)
Wall Street analysts rate BNTC "Buy" based on 7 analysts, with a mean price target of USD 24.33 (range USD 17–32), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 24.33 |
| High Target | USD 32 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (BNTC)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.26 vs est -0.27 ▲ beat |
| 2026-03-31 | USD -0.24 vs est -0.28 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.23 ▼ miss |
| 2025-09-30 | USD -0.22 vs est -0.36 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (BNTC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -33.21% |
| Debt / Equity | 0 |
| Current Ratio | 34 |
| Total Cash | $179.97M |
| Total Debt | $762,000 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (BNTC)
Nexqual rates Benitec Biopharma Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $180M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$17M (TTM) |
| Efficiency | Critical — ROE -33%, ROA -22.7% |
Ownership (BNTC)
| Insider Ownership | +2.51% |
|---|---|
| Institutional Ownership | +96.07% |
| Shares Outstanding | 34.88M |
| Float | 18.45M |
| Short % of Float | +10.23% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (BNTC)
Benitec Biopharma Inc. is led by Jerel A. Banks (age 49), Executive Chairman & CEO, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Executive Chairman & CEO | Jerel A. Banks (age 49) |
|---|---|
| CFO & Secretary | Megan Joan Boston B.Com., C.A. (age 52) |
| Chief Operating Officer | Sophie Mukadam (age 44) |
| Senior Vice President of Manufacturing | Claudia Kloth |
Major Backers & Investors (BNTC)
Notable institutional backers of Benitec Biopharma Inc. include Montanova Capital LLC, Jupiter Topco LLC, Franklin Resources, Inc., according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Montanova Capital LLC | 33.11% |
| Jupiter Topco LLC | 7.11% |
| Franklin Resources, Inc. | 6.92% |
| Adage Capital Partners GP L.L.C. | 6.08% |
| RA Capital Management, L.P. | 5.3% |
| Nantahala Capital Management, LLC | 4.27% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 3.87% |
| Simplify Asset Management, Inc. | 2.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.07% |
| Vanguard Group | 5.7% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt